BioBounce.com provides two approaches to take advantage of the Biotech sector. Decide what works best for you!

BIB/BIS Trend Following Trading System

The first approach is our BIB/BIS ETF trading system. BIB and BIS are leveraged ETFs that produce 2x the daily return of IBB. By Utilizing these two ETFs, we can profit from both the long and short sides of the sector, creating a significant performance advantage compared to a buy and hold strategy for IBB alone. See our performance above!

Because you only need to focus on BIB and BIS, this system is ideal for those that work full time or do not want to manage multiple individual positions. The BIB/BIS system shields you from exposure to major gap down catalyst events such as clinical trial data releases, FDA approval decisions, earnings reports, equity dilutions or anything else that you need to follow closely when trading individual biotech stocks.

Here is how it works:

Take a starting dollar amount that you are comfortable allocating and dedicate it solely to trading only BIB and BIS

When a buy signal occurs on BIB or BIS, we add either to our watchlist, with an entry price and initial hard stop.

If the trade triggers, take your previously decided dollar amount and use it to buy the watchlist ticker (either BIB or BIS)

Each night, we will update the hard stop price.

Hold the position until the hard stop hits, or if you receive an email alert at the close of trading sell the next day at open.

At this point, the system will have you in cash.

When another buy signal occurs, we will add either BIB or BIS back to the watchlist.

Take your total balance from the previous trade, and roll it all into the next once the entry price triggers. For example, if you put $10K into the first trade and it made 10%, you would roll the 11K balance into the next trade.

Keep following this process over and over.

Check out our performance above! Here are some additional stats:

The system makes on average about one trade per month

with an average holding period of around 15-20 days.

The average winning trade equals 11%

The average losing trade is -5%

Individual Biotech Stocks

If you prefer to manage multiple individual stocks then our watchlist of stocks may be more suitable to your needs. When the Biotech sector is in an uptrend (when we are in a BIB position) we will automatically populate our watchlist with Biotech stocks with near term catalysts. Once the Biotech sector trend goes bearish (when we are in a BIS position) no new tickers will be added and the current positions we are in will be continually updated until they get stopped out.

Here is how it works:

When BIB triggers within the BIB/BIS system, we will then start populating our individual Biotech Watchlist with stocks that have a high technical probability of entering an uptrend.

When up to 10 trades trigger and move to the holdings list, we will not add any further tickers. If one stops out, then we add one more to the watchlist to get the list back to 10.

Because it is impossible to predict which trades will be profitable, it is recommended you use the same dollar amount for each trade to balance risk. For example, if you put $5k into ticker ABCD and it goes up 10% but put $15K into ticker WXYZ and it loses 8%, you’d be down $700. Conversely, if you put $10k into each ticker, you’d be up $200.

Buy the stock at it’s indicated entry price and immediately set the indicated hard stop price.

Check in each night or morning and update your hard stop if necessary. If you get an alert after market close to sell the next morning, simply do so.

Use the same process for each trade you enter

If you are a member, you can email me (BioBounce@BioBounce.com) any of your stock picks. If it sets up according to our methodology, we may add it to the watchlist!

Regardless of your trading experience and/or time sensitivities, we have a solution for you! We provide the trades; you provide the execution!

Check us out free of charge for 30 days! Register now and join our community!

Sign up for a free 30 day trial now!

The free trial is No Risk, No Obligation, and No Credit Card Required.

Once your trial ends, you can use the link inside our members area to begin your subscription:

Up to the minute ticker tracking, email updates with position adjustments, and monthly detailed explanations of the current state of the biotech markets.

"How often does the system place a trade?"

Average is once per month - Several times were in cash for up to 2 weeks - Out of 2 calendar years (365*2) 730 days, we were in a position 416 days of about 57% of the time.

"How do you determine when to take a trade?"

Wouldn't you like to know?

"What is a leveraged ETF?"

A leveraged exchange-traded fund (ETF) is a fund that uses financial derivatives and debt to amplify the returns of an underlying index. Leveraged ETFs are available for most indexes, such as the Nasdaq 100 and the Dow Jones Industrial Average.

"Can you apply your system to other sectors?"

The system can be applied to any ticker.

"What was the max drawdown you experienced trading this system?"

-14.65%

AlgoSniffer, LLC is the Publisher of BioBounce.com and @BioBounceAlerts. AlgoSniffer, LLC is not a Registered Investment Advisor.
BioBounce.com and @BioBounceAlerts are for informational purposes only and AlgoSniffer, LLC accepts no responsibility for any monetary losses incurred from use of the information provided.
Biotechnology is a highly volatile sector, and presents higher than average risk. As a subscriber of our service, you are responsible for your own due diligence regarding any and all tickers we provide on our watchlist.
General Information on the Regulation of Investment Advisers
Division of Investment Management
Exclusions From the Definition
Publishers of bona fide newspapers, news magazines, and business or financial publications of general and regular circulation. Under a decision of the United States Supreme Court, to enable a publisher to qualify for this exclusion, a publication must satisfy three elements: (1) the publication must offer only impersonal advice, i.e., advice not tailored to the individual needs of a specific client, group of clients, or portfolio; (2) the publication must be "bona fide," containing disinterested commentary and analysis rather than promotional material disseminated by someone touting particular securities, advertised lists of stocks "sure to go up," or information distributed as an incident to personalized investment services; and (3) the publication must be of general and regular circulation rather than issued from time to time in response to episodic market activity or events affecting the securities industry. See Lowe v. Securities and Exchange Commission, 472 U.S. 181 (1985).
source: http://www.sec.gov/divisions/investment/iaregulation/memoia.htm